Are We Over-Diagnosing Cannabis Use Disorder in Prescribed Medical Cannabis Patients?
prescription cannabis use disorder: A new Addiction journal study of 2,054 Australians prescribed medical cannabis found that removing tolerance and withdrawal from Cannabis Use Disorder criteria cut apparent disorder rates among as-prescribed patients…
Cannabis Use, Cannabis Use Disorder Are Not The Same
Cannabis use and cannabis use disorder showed partly different genetic relationships with selected brain-imaging traits in a large 2026 analysis. The findings support treating use and disorder as related but noninterchangeable research phenotypes. They…
UK Medical Cannabis Use: What a New National Survey Found
A new UK national survey examined uk medical cannabis prescriptions and their link to high-risk use. The study found prescribed users more frequently used processed products and screened positive for high-risk use. These findings highlight the need for…
PTSD and Solitary Substance Use: Different Risks for Alcohol and Cannabis
A recent study reveals that PTSD solitary alcohol use risk is significantly linked to increased alcohol-related problems, unlike solitary cannabis use. This finding challenges assumptions that all solitary substance use carries the same risk for those…
CED Cannabis Science Digest: Key Psychosis and Craving Signals
This digest highlights cannabis psychosis vulnerability signals, focusing on sex-specific risk differences, craving subtypes, and EEG brain-pattern changes in cannabis use disorder. These signals improve psychiatric interpretation without claiming…
Progesterone for Cannabis Use Disorder: What the New Stress-Response Trial Actually Found
A July 2026 trial on progesterone cannabis use disorder research found it reduced stress-linked craving in females. The study was brief and focused on laboratory stress responses. It highlights the need for sex-specific research in cannabis use disorder…
CED Cannabis Science Digest: 3 CUD, Dosing, and Neurobiology Signals Worth Watching
This digest presents 2026 cannabis use disorder research focusing on three key signals: cannabis use disorder recovery biology, THC pharmacokinetic variability, and cannabinoid neurobiology. The included studies provide educational insights without…
GLP-1 Medications May Quiet the Craving Behind Addiction
A landmark BMJ study published June 3, 2026 found that GLP-1 receptor agonists like semaglutide significantly reduced both the development and severity of substance use disorders in over 600,000 U.S. veterans. Cannabis use disorder risk dropped 14%,…
Modes of cannabis administration, cannabis and tobacco co-use, and associations
This study highlights that adults who co-use cannabis with tobacco are more likely to use combustible methods, leading to worse respiratory outcomes and higher cannabis consumption.
SAMHSA’s 2026 Clinical Guidance for Physicians and Patients on Cannabis Use Disorder
SAMHSA released a formal 2026 advisory instructing primary care physicians to evaluate cannabis use based on clinical signs of harm, not simply patient use. Dr. Caplan breaks down what this federal guidance actually says, where current diagnostic tools…